This abstract answers alot: Doubling the mOS al
Post# of 154503
(Total Views: 317)
Posted On: 06/25/2025 11:53:50 PM
This abstract answers alot:
Doubling the mOS alone, again validates our patents:
Non toxic. Angiogenisis. Small & large vessels. Etc..
"Adverse events (AEs) were limited, with 7 reported in the trial (5G1 & 2G2), with no serious AEs"
Only 7 from 5 people? --- unheard of.
Just 1 person always has a laundry list of AE's.
Looking frwd to the 1600 patient safety report.
"One patient with a solitary hepatic metastasis underwent liver resection following a reduction (43%) after FOLFOX + leronlimab, and remains alive with no evidence of disease (NED) at ~57 months.
Tumor shrinkage & another cancer-free @ NED.
Remember, Trovdely was approved on likely, to shrink tumors.
Doubling the mOS, combined with mTNBC & pooling trial data, we qualify for any program the FDA has.
Now we know CRC started before mTNBC by a few months.
That explains no PD-L1.
Then PD-L1 @ mTNBC.
1st CRC trial dosed 5 patients.
Our current CRC is dosing 5 patients @ 350.
Why ?!!?
We don't know, but i'm going to cut mgt slack on it & say ok, by FDA choice. Why ?
The 1st CRC protocol says --- 525mg.
Why 350mg's in this CRC abstract?
Current CRC with PD-L1 measurements.
No more drawn out delays on appropriate dosing.
Let's get the cold/hot confirmation follow-up.
Data pool Hiv, Hiv-MDR, mTNBC & CRC to the FDA, for a not to distant full approval process
Remaining trials also kick-off
Partner agreement & funding....
& or govt funding, foundations,WHO, DOD, EU, etc...
NASDAQ....
Opening Bell
Doubling the mOS alone, again validates our patents:
Non toxic. Angiogenisis. Small & large vessels. Etc..
"Adverse events (AEs) were limited, with 7 reported in the trial (5G1 & 2G2), with no serious AEs"
Only 7 from 5 people? --- unheard of.
Just 1 person always has a laundry list of AE's.
Looking frwd to the 1600 patient safety report.
"One patient with a solitary hepatic metastasis underwent liver resection following a reduction (43%) after FOLFOX + leronlimab, and remains alive with no evidence of disease (NED) at ~57 months.
Tumor shrinkage & another cancer-free @ NED.
Remember, Trovdely was approved on likely, to shrink tumors.
Doubling the mOS, combined with mTNBC & pooling trial data, we qualify for any program the FDA has.
Now we know CRC started before mTNBC by a few months.
That explains no PD-L1.
Then PD-L1 @ mTNBC.
1st CRC trial dosed 5 patients.
Our current CRC is dosing 5 patients @ 350.
Why ?!!?
We don't know, but i'm going to cut mgt slack on it & say ok, by FDA choice. Why ?
The 1st CRC protocol says --- 525mg.
Why 350mg's in this CRC abstract?
Current CRC with PD-L1 measurements.
No more drawn out delays on appropriate dosing.
Let's get the cold/hot confirmation follow-up.
Data pool Hiv, Hiv-MDR, mTNBC & CRC to the FDA, for a not to distant full approval process
Remaining trials also kick-off
Partner agreement & funding....
& or govt funding, foundations,WHO, DOD, EU, etc...
NASDAQ....
Opening Bell
(2)
(0)